Plasmid DNA Vaccine Development Guidance Under Revision At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Center for Biologics Evaluation & Research is proposing to no longer require preclinical autoimmune studies. Other proposed revisions to the 1996 guidance include accelerating the dosing schedule and using the highest dose planned for clinical administration in toxicity studies.